# US 2019/0240238 A1 · Cycloartane tetracyclic triterpenoid compound, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240238 A1
- Document ID: US20190240238A1
- Status: Published application
- Kind: A1
- Application number: 16/083,390
- Filed: 2017-02-03
- Published: 2019-08-08
- Earliest claimed: 2016-10-25
- Assignees: Hefei Cosource Pharmaceuticals Co., Ltd; Hefei Blooming Drug Safety Evaluation Co., Ltd.
- Applicants: Hefei Cosource Pharmaceuticals Inc.; Hefei Blooming Drug Safety Evaluation Co., Ltd.
- Inventors: Shanchun Zhang; Shu Gao; Xiaorong Lu; Hongzhang Sun; Yijun Bao; Bin Yang; Jiashi Peng
- Web page: https://patentgrep.com/patent/US20190240238A1

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of natural medicine and pharmaceutical chemistry, and in particular relates to a cycloartane tetracyclic triterpenoid compound (I), a preparation method thereof and the medical use thereof. The pharmacodynamic tests demonstrate that the compound of the present invention has a pharmacodynamic activity on heart and cerebral vessels and can be used to prevent or treat cardiovascular and/or cerebrovascular diseases such as arrhythmia, myocardial infarction, and coronary heart disease or the like.

## Claims

### Claim 1

A compound of general formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof:
wherein,
X represents —OH, ═O, ═NORa, or ═NOCORb, wherein Ra represents hydrogen, methyl, ethyl, propyl, isopropyl, or butyl; Rb represents C1-C10 alkyl, C2-C10 alkenyl, or C6-C12 aryl optionally having a substituent, wherein the substituent is selected from halogen, methyl, ethyl, hydroxy, amino, sulfhydryl, phenyl, methoxy, ethoxy, cyano, nitro, acetoxy, acetylamino, carboxy, a methyl carboxylate group, or an ethyl carboxylate group;
R1 represents hydrogen, hydroxy, ORc, or OCORd, wherein Rc represents methyl, ethyl, propyl, isopropyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; Rd represents C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 alkenyl, C6-C12 aryl, or heteroaryl optionally having a substituent, the heteroaryl being a monocyclic or fused ring having 5 to 12 ring atoms and containing 1 to 4 ring heteroatoms selected from N, O, or S, the remaining ring atoms being C; wherein the substituent is selected from halogen, trifluoromethyl, methyl, ethyl, hydroxy, amino, sulfhydryl, phenyl, methoxy, ethoxy, cyano, nitro, acetoxy, acetylamino, carboxy, a methyl carboxylate group, or an ethyl carboxylate group;
R2 is selected from hydrogen, halogen, methyl, ethyl, propyl, isopropyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; and
R3 is selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl,
with a compound wherein X represents ═O, both R1 and R2 represent H, and R3 represents CH3 being excluded.

### Claim 2 (depends on 1)

The compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
X represents ═O or ═NOH;
R1 represents hydrogen, hydroxy, or OCORd, wherein Rd is C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 alkenyl, or C6-C12 aryl optionally having a substituent; wherein the substituent is selected from halogen, trifluoromethyl, methyl, ethyl, hydroxy, amino, sulfhydryl, phenyl, methoxy, ethoxy, cyano, nitro, acetoxy, acetylamino, carboxy, a methyl carboxylate group, or an ethyl carboxylate group;
R2 represents hydrogen, fluorine, or methyl;
R3 represents hydrogen, methyl, ethyl, propyl, isopropyl, or cyclopropyl.

### Claim 3 (depends on 1)

The compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein:
X represents ═O, and R2═R3═H;
R1 represents hydrogen, hydroxy, or OCORd, wherein Rd is C1-C10 alkyl, vinyl, or phenyl optionally having a substituent, wherein the substituent is halogen, trifluoromethyl, methyl, ethyl, hydroxy, amino, sulfhydryl, phenyl, methoxy, ethoxy, cyano, nitro, acetoxy, acetylamino, carboxy, a methyl carboxylate group, or an ethyl carboxylate group.

### Claim 4 (depends on 3)

The compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 3, wherein:
R1 represents:

### Claim 5 (depends on 1)

The compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is a compound selected from any one of the following structures:
(3β,5α)-4,4,14-trimethyl-3-(methylamino)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-3-(methylamino)-9,19-cyclopregnan-16-en-20-one oxime;
(3β,5α)-4,4,14-trimethyl-3-(methylamino)-20-methoxyimino-9,19-cyclopregnan-16-ene;
(3β,5α)-4,4,14-trimethyl-21-hydroxy-3-(methylamino)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-21-acetoxy-3-(methylamino)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-3-(methylamino)-21-(3-carboxypropionyloxy)-9,19-cyclopregnan-16-en-20-one hydrochloride;
(3β,5α)-4,4,14-trimethyl-3-(methylamino)-21-(2-carboxybenzoyloxy)-9,19-cyclopregnan-16-en-20-one hydrochloride;
(3β,5α)-4,4,14-trimethyl-3-(methylamino)-21-(benzoyloxy)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-3-(methylethylamino)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-21-hydroxy-3-(dimethylamino)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-3-(methylcyclopropylamino)-9,19-cyclopregnan-16-en-20-one;
(3β,5α)-4,4,14-trimethyl-16-fluoro-3-(methylamino)-9,19-cyclopregnan-16-en-20-one; or
(3β,5α)-4,4,14,16-tetramethyl-3-(methylamino)-9,19-cyclopregnan-16-en-20-one.

### Claim 6 (depends on 1)

The compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the pharmaceutically acceptable salt is a salt formed from the compound of formula (I) with an acid selected from hydrochloric acid, hydrobromic acid, methanesulfonic acid, isethionic acid, sulfuric acid, acetic acid, trifluoroacetic acid, maleic acid, benzenesulfonic acid, toluenesulfonic acid, nitric acid, phosphoric acid, boric acid, tartaric acid, citric acid, succinic acid, benzoic acid, ascorbic acid, or salicylic acid.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 2)

A pharmaceutical composition comprising the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 2, and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 3)

A pharmaceutical composition comprising the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 3, and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 4)

A pharmaceutical composition comprising the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 4, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 5)

A pharmaceutical composition comprising the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 5, and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 6)

A pharmaceutical composition comprising the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof according to claim 6, and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method of treating a cardiovascular or cerebrovascular disease, comprising administering to a subject in need thereof the compound of general formula (I), the optical isomer thereof or the pharmaceutically acceptable salt thereof of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cardiovascular or cerebrovascular disease is arrhythmia, coronary atherosclerotic heart disease, asymptomatic myocardial ischemia, ischemic cardiomyopathy, heart failure, or a complication thereof.
